Background and Importance Dihydropyrimidine dehydrogenase (DPYD) is a key enzyme in
the metabolism of fluoropyrimidines. Patients with deficiency in DPYD are at great risk of …

e15517 Background: DPYD deficiency is present in 3-5% of patients. The risk of treatment-
related death in DPYD mutation carriers who receive fluoropyrimidine chemotherapy has …

Among cancer patients treated with fluoropyrimidines, 10–40% develop severe toxicity.
Polymorphism of the dihydropyrimidine dehydrogenase (DPYD) gene may reduce DPD …

Variations in the activity, up to absolute deficiency, of the enzyme dihydropyrimidine
dehydrogenase (DPD), result in the occurrence of adverse reactions to chemotherapy, and …

Gastrointestinal toxicity due to chemotherapeutic drugs is a common problem in cancer
patients. Chemotherapy-related diarrhea is most commonly described with fluoropyrimidines …

Background: The fluoropyrimidine anticancer drug, especially 5-fluorouracil (5-FU) and its
prodrug capecitabine are still being the backbone of chemotherapeutic regimens for …

Background Genetic variants of dihydropyrimidine dehydrogenase (DPYD) gene can result
in varied enzymatic activity and potential toxicity when receiving 5-FU chemotherapy …

Pharmacists say testing patients for DPYD gene variants before starting fluoropyrimidine
chemotherapy is the right thing to do—even though US clinical practice guidelines don't yet …

Mutations of the DPD gene results in severe DPD deficiency, DPD deficient patients have
shown splice-site polymorphism, DPD* 2A, IVS14+ G> A (ie, a G to A alteration in the …

Background In the era of precision medicine, the suitability of fluoropyrimidine therapies in
clinical oncology can be checked by pharmacogenetic investigations of single patients, thus …